Domestic pharma's Acute was disrupted in FY21 due to Covid and most businesses are sitting on a low FY21 base. They can grow handsomely not only this fiscal, but also medium to long term. If a debt-free businesses can do 20-25% ROCE despite Covid, what can be the FY23e EV/Sales?

More from Sajal Kapoor

@oldschoolinvest I said 20-25% #CDMO (Synthesis) growth going forward in @IIC_Conference June 2020 conclave. They have delivered better than my expectations.

Never Knowingly Misguide.

Money making and fake advisory/PMS propaganda has never been my agenda

More from Uvlearnings

You May Also Like